EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Protection Induced by a Novel Circumsporozoite Protein Malaria Vaccine is Associated with the Quality of Antibody Responses

Paul M Robben iD, Jack N Hutter, Lei Zhu, Heather Galli, Michael A Koren, James E Moon, Dallas R Brown, Tanisha M Robinson, Elizabeth H Duncan, Arnel D Belmonte iD, Martha Sedegah, Ines Lakhal-Naouar und 10 weitere

The Journal of Infectious Diseases · 04.11.2026

DOI: 10.1093/infdis/jiag533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 04.11.2026. Verfasst von Paul M Robben und 21 weiteren Autor:innen. Beteiligte Einrichtung: Biologics Research and Development Branch, Center for Military Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, Ma…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malaria remains an intractable global health problem. We report results of a single-center, open-label Phase 1 trial of a nearly full-length soluble recombinant Plasmodium falciparum CSP (FMP013) formulated in the Army Liposome Formulation containing QS21 (ALFQ).

Methods

Healthy malaria-naïve adults (n=29) were enrolled into three groups. Standard (STD) group volunteers received FMP013/AFLQ (20 µg/0.5 mL) on a 0-1-2-month schedule (n=10). Delayed group (DEL) received the same dose on a 0-1-6-month schedule (n=10). Delayed Fractional Dose (DFD) volunteers (n=9), vaccinated at 0-1-6-months, received a fractional third dose (4 µg/0.1 mL). Immunized and unvaccinated control participants underwent P. falciparum-infected mosquito bite challenge three weeks after the third immunization and safety, tolerability, efficacy, and immunogenicity were analyzed.

Results

All regimens were well tolerated. 5 of 9 DEL (vaccine efficacy [VE], 55.6%, 95% confidence interval [CI], 21.2-86.3%; P< 0.001), 1 of 7 DFD (VE 14.3%, CI 0.0-57.9%), and 1 of 9 STD (VE 11.1%, CI 0.0-48.3%) subjects had sterile protection. Delayed blood-stage infection was observed in 3 DEL, 2 DFD and 1 STD subjects. The FMP013/ALFQ vaccine elicited C-terminal biased responses and protection in the DEL regimen was associated with higher C-terminal avidity, and junction, minor repeat epitope-specific responses.

Conclusions

A soluble protein CSP vaccine, akin to particle vaccines, can elicit a protective response when delivered using a potent adjuvant and an extended vaccination schedule. These data encourage further evaluation of FMP013/ALFQ efficacy and durability in the field.

Schlagwörter

Stichwörter der Autor:innen

ALFQPlasmodium falciparumPre-erythrocytic vaccinecircumsporozoite proteincontrolled human malaria parasite infectionefficacyimmunogenicitymalariasafetyvaccine regimen

Autor:innen und Institutionen

  • Biologics Research and Development Branch, Center for Military Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Clinical Trial Center, Center for Enabling Capabilities, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Naval Medical Research Command, Silver Spring, Maryland, USA.
  • General Dynamics Information Technology, Inc., Falls Church, Virginia, USA.
  • Henry M Jackson Foundation for Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
  • Diagnostics and Countermeasures Branch, US Military HIV Research Program, Center of Infectious Disease, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.

ORCID-Profile: Paul M Robben, Arnel D Belmonte, Wathsala Wijayalath, Evelina Angov, Elke S Bergmann-Leitner, Sheetij Dutta

Zitieren

APA

Robben, P. M., Hutter, J. N., Zhu, L., Galli, H., Koren, M. A., Moon, J. E., Brown, D. R., Robinson, T. M., Duncan, E. H., Belmonte, A. D., Sedegah, M., Lakhal-Naouar, I., Peel, S., Bolton, J. S., Wijayalath, W., Soisson, L., Rao, M., Matyas, G. R., Angov, E., …, & Dutta, S. (2026). Protection Induced by a Novel Circumsporozoite Protein Malaria Vaccine is Associated with the Quality of Antibody Responses. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag533

Vancouver

Robben PM, Hutter JN, Zhu L, Galli H, Koren MA, Moon JE, et al. Protection Induced by a Novel Circumsporozoite Protein Malaria Vaccine is Associated with the Quality of Antibody Responses. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag533

BibTeX
@article{Robben2026,
  author = {Robben, Paul M and Hutter, Jack N and Zhu, Lei and Galli, Heather and Koren, Michael A and Moon, James E and Brown, Dallas R and Robinson, Tanisha M and Duncan, Elizabeth H and Belmonte, Arnel D and Sedegah, Martha and Lakhal-Naouar, Ines and Peel, Sheila and Bolton, Jessica S and Wijayalath, Wathsala and Soisson, Lorraine and Rao, Mangala and Matyas, Gary R and Angov, Evelina and Bergmann-Leitner, Elke S and Regules, Jason A and Dutta, Sheetij},
  title = {Protection Induced by a Novel Circumsporozoite Protein Malaria Vaccine is Associated with the Quality of Antibody Responses},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag533}
}
Kostenlos starten →